Genmab | GEN - Ebitda


Genmab reported DKK186M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Almirall EUR 114.07M 60.37M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
argenx SE USD 404.12M 17.08M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bayer EUR 4.45B 2.49B Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Demant DKK 2.76B 165M Dec/2025
Exelixis USD 258.29M 15.43M Mar/2026
Fresenius Medical Care EUR 824M 250M Mar/2026
Genmab DKK 186M 291M Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
GN Store Nord DKK 491M 136M Mar/2026
GRIFOLS EUR 347.45M 210K Dec/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Insmed USD -148.3M 165.88M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
Merck EUR 1.53B 87M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
UCB EUR 1.6B 570M Dec/2025